Clinical Trial: Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma
Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional
Official Title: Comparative Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma
Brief Summary: The purpose of this study is to compare effects of erlotinib and pemetrexed as maintenance therapy for lung adenocarcinoma. Primary Outcome is the progression free survival (PFS). Based on prediction of different potential benefit groups, this study may help the oncologist to optimize and improve the maintenance therapy plan for lung adenocarcinoma.
Detailed Summary:
Sponsor: Hunan Province Tumor Hospital
Current Primary Outcome: Progression free survival (PFS) [ Time Frame: two years ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Overall survival (OS) [ Time Frame: two years ]
- Clinical benefit rate (CBR) [ Time Frame: two years ]
- Objective response rate (ORR) [ Time Frame: two years ]
- The adverse reaction [ Time Frame: two years ]
- Time to progression (TTP) [ Time Frame: two years ]
Original Secondary Outcome: Same as current
Information By: Hunan Province Tumor Hospital
Dates:
Date Received: March 22, 2015
Date Started: May 2015
Date Completion: January 2019
Last Updated: March 25, 2015
Last Verified: March 2015
